AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

AC Immune S.A.NASDAQ: ACIU

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares declines year over year

Q1 FY2026 weighted avg shares of 98.67M shares fell 1.7% year over year, ahead of the -2.5% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.7% holds above the trailing-twelve-month pace of -2.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.67M-2.5% QoQ
Last fiscal yearDec 2025
100.75M+1.1% YoY
LTMMar 2026
99.9M-2.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.7%——
1 year+1.1%——
3-year CAGR+6.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
100.75M CHF
Year-over-year change
+1.1%
4-year CAGR
+7.7%

Weighted Avg Shares vs competitors

How ACIU compares with its peers on the latest reported figures

  • ACIU's LTM Mar 2026 weighted avg shares of 99.9M shares is the 4th highest of the 11 companies compared; the peer median is 45.83M shares.
  • Its year-over-year change of -2.5% is the lowest of 10, against a peer median of +10.2%.
  • Over three fiscal years its annual growth of +6.4% compares with a peer median of +9.0%.
ACIU Competitors Peer median
Weighted Avg Shares for ACIU and competitors
Company Period LTM YoY 3-year CAGR
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 202684.87M +21.1%+8.2%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
Peer median (excluding ACIU) 45.83M+10.2%+9.0%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.